Illumina Appoints Marc Stapley as Senior Vice President and CFO
News Jan 05, 2012
Illumina, Inc. has announced that it has named Marc Stapley, former Senior Vice President, Finance, at Pfizer and Americas Chief Financial Officer at Alcatel-Lucent, to the position of Senior Vice President and Chief Financial Officer.
Stapley will report to President and Chief Executive Officer Jay Flatley and will oversee Illumina’s finance, accounting, facilities and investor relations functions.
He will also become part of Illumina’s executive management team, which is responsible for directing all aspects of company strategy, planning and operations.
“Marc is an ideal fit for the fast-paced culture of Illumina,” said Jay Flatley. “He is a dynamic finance leader whose experience spans leading high-tech and pharmaceutical companies where he has helped transform the finance functions, directed ERP implementations, effectively identified cost reduction initiatives and led acquisition integration efforts.”
“I am honored to take the role of Illumina’s CFO and join such a world-class team,” said Stapley.
Stapley continued, “The Company is in a critical growth and development stage, and I look forward to supporting the continued innovation and performance that the company has delivered over many years.”
Stapley joins Illumina from Pfizer where he served as Senior Vice President responsible for global financial processes and systems, leading integration efforts in both the Wyeth and King Pharmaceutical acquisitions and providing oversight to the company’s largest technology investment program.
Prior to Pfizer, he served in a variety of senior finance roles at Alcatel-Lucent, including Americas CFO. He also worked as Finance Director and Controller for several groups at Cadence Design Systems.
Stapley began his career as an Auditor at Coopers & Lybrand. Stapley holds a First Class BSc (Honors) in Mathematics from The University of Reading (England) and is a member of the Institute of Chartered Accountants in England and Wales.
Stapley is expected to join Illumina on January 20, 2012. At that time he will assume the CFO responsibilities currently held by Christian Henry.
Henry, who for the past two years has been serving in both the CFO role and as GM of the Company’s Genetic Analysis business (formerly Life Sciences), will now be able to fully dedicate his time to leading our Genetic Analysis business.
“I would like to thank Christian for the outstanding contributions he has made to Illumina in the CFO role,” said Jay Flatley.
Flatley continued, “Since 2005, Christian has developed a world-class finance organization and led multiple corporate financings, acquisitions and facility relocations. I look forward to the impact he can make by solely focusing on driving our Genetic Analysis Business.”
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
Study Indicates 75% of Human Genome is Non-functionalNews
An evolutionary biologist at the University of Houston has published new calculations that indicate no more than 25 percent of the human genome is functional.READ MORE
Edith Heard Unanimously Selected as Next Director General of EMBLNews
At its 53rd meeting yesterday, EMBL Council selected Edith Heard as the organization’s fifth Director General. Heard’s mandate is scheduled to begin 1 January 2019.READ MORE
Comments | 0 ADD COMMENT
EMBL Course: Next Generation Sequencing: RNA Sequencing Library Preparation
Apr 23 - Apr 27, 2018
EMBO Practical Course: Microbial Metagenomics: A 360º Approach
Apr 23 - Apr 30, 2018
EMBL Course: Next Generation Sequencing: Whole Genome Sequencing Library Preparation
Apr 16 - Apr 20, 2018
EMBL Course: Introduction to Next Generation Sequencing
Apr 09 - Apr 12, 2018